{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:25:09Z","timestamp":1793550309762,"version":"4.5.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/https:\/\/doi.org\/10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/https:\/\/doi.org\/10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.pharmthera.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T12:08:59Z","timestamp":1526126939000},"page":"91-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":556,"special_numbering":"C","title":["Autism Spectrum Disorder: Classification, diagnosis and therapy"],"prefix":"10.1016","volume":"190","author":[{"given":"Samata R.","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenia","family":"Gonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.05.007_bb0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/00004583-199510000-00012","article-title":"Childhood-onset schizophrenia: The severity of premorbid course","volume":"34","author":"Alaghband-Rad","year":"1995","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/bs.pbr.2014.11.029","article-title":"Apollo's gift: New aspects of neurologic music therapy","volume":"217","author":"Altenm\u00fcller","year":"2015","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/aur.1692","article-title":"Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder","volume":"10","author":"Alvares","year":"2017","journal-title":"Autism Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.05.007_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.chc.2008.06.009","article-title":"Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders","volume":"17","author":"Aman","year":"2008","journal-title":"Child and Adolescent Psychiatric Clinics of North America"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0025","series-title":"Diagnostic and statistical manual of mental disorders: DSM-IV-TR","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2007.07.036","article-title":"Use of antidepressant medications during pregnancy: A multisite study","volume":"198","author":"Andrade","year":"2008","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/mp.2014.74","article-title":"Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: A randomized controlled trial","volume":"20","author":"Aoki","year":"2015","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01837709","article-title":"Die \u201cAutistischen Psychopathen\u201d im Kindesalter [autistic psychopaths in childhood]","volume":"117","author":"Asperger","year":"1944","journal-title":"Archiv f\u00fcr Psychiatrie und Nervenkrankheiten (in German)"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0045","author":"Autism Speaks"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/1381612822666151112151529","article-title":"Autism: Pathophysiology and promising herbal remedies","volume":"22","author":"Bahmani","year":"2016","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0055","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"461","article-title":"Pharmacotherapy of psychosis and mania","author":"Baldessarini","year":"2005"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0060","article-title":"Herbal medicine treatment for children with autism spectrum disorder: A systematic review","volume":"8614680","author":"Bang","year":"2017","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pneurobio.2015.09.007","article-title":"Behavioral, perceptual, and neural alterations in sensory and multisensory function in autism spectrum disorder","volume":"134","author":"Baum","year":"2015","journal-title":"Progress in Neurobiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0070","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.nurt.2010.06.001","article-title":"Medical comorbidities in autism: Challenges to diagnosis and treatment","volume":"7","author":"Bauman","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.05.007_bb0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2217\/phe.10.45","article-title":"Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6\u201317\u202fyears","volume":"4","author":"Blankenship","year":"2010","journal-title":"Pediatric Health"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0080","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1469-7610.1994.tb02300.x","article-title":"A case-control family history study of autism","volume":"35","author":"Bolton","year":"1994","journal-title":"Journal of Child Psychology and Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1162\/089892903321208169","article-title":"Enhanced pitch sensitivity in individuals with autism: A signal detection analysis","volume":"15","author":"Bonnel","year":"2003","journal-title":"Journal of Cognitive Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2015.3356","article-title":"Antidepressant use during pregnancy and the risk of autism spectrum disorder in children","volume":"170","author":"Boukhris","year":"2016","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0095","doi-asserted-by":"crossref","first-page":"258589","DOI":"10.1155\/2015\/258589","article-title":"Complementary and alternative therapies for autism spectrum disorder","volume":"2015","author":"Brondino","year":"2015","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S1461145701002280","article-title":"Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: A pilot study","volume":"4","author":"Buchsbaum","year":"2001","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/0883073808322666","article-title":"Tourette syndrome and comorbid autism spectrum disorders","volume":"24","author":"Burd","year":"2009","journal-title":"Journal of Child Neurology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/pcn.12627","article-title":"Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder","author":"Cai","year":"2018","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1362361307070992","article-title":"Tics and Tourette syndrome in autism spectrum disorders","volume":"11","author":"Canitano","year":"2007","journal-title":"Autism"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/978-1-4614-0653-2_28","article-title":"Tourette syndrome","volume":"724","author":"Cavanna","year":"2012","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.05.007_bb0125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2015.0101","article-title":"Increased functional connectivity between subcortical and cortical resting-state networks in autism spectrum disorder","volume":"72","author":"Cerliani","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10803-013-1973-x","article-title":"Gastrointestinal problems in children with autism, developmental delays or typical development","volume":"44","author":"Chaidez","year":"2014","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.31887\/DCNS.2015.17.2\/tchandrasekhar","article-title":"Challenges in the diagnosis and treatment of depression in autism spectrum disorder across the lifespan","volume":"17","author":"Chandrasekhar","year":"2015","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6503a1","article-title":"Prevalence and characteristics of autism spectrum disorder among children aged 8\u202fyears\u2014Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012","volume":"65","author":"Christensen","year":"2016","journal-title":"MMWR Surveillance Summaries"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0145","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1097\/00004703-200604002-00013","article-title":"Early intensive behavioral treatment: Replication of the UCLA model in a community setting","volume":"27","author":"Cohen","year":"2006","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4088\/JCP.v65n0119","article-title":"The effect of a switch to ziprasidone in an adult population with autistic disorder: Chart review of naturalistic, open-label treatment","volume":"65","author":"Cohen","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0155","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","article-title":"A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders","volume":"65","author":"Corson","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/104454602760386932","article-title":"A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders","volume":"12","author":"Couturier","year":"2002","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0165","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archgenpsychiatry.2011.73","article-title":"Antidepressant use during pregnancy and childhood autism spectrum disorders","volume":"68","author":"Croen","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10803-013-1899-3","article-title":"Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial","volume":"44","author":"Dadds","year":"2014","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0175","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/DBP.0b013e31829f676c","article-title":"Cognitive behavioral therapy for children with autism: Review and considerations for future research","volume":"34","author":"Danial","year":"2013","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nn1611","article-title":"Understanding emotions in others: Mirror neuron dysfunction in children with autism spectrum disorders","volume":"9","author":"Dapretto","year":"2006","journal-title":"Nature Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0185","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s13311-012-0126-9","article-title":"Treatment for co-occurring attention deficit\/hyperactivity disorder and autism spectrum disorder","volume":"9","author":"Davis","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0190","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.rasd.2010.02.006","article-title":"Anxiety symptoms across the lifespan in people diagnosed with autistic disorder","volume":"5","author":"Davis","year":"2011","journal-title":"Research in Autism Spectrum Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0195","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1542\/peds.2009-0958","article-title":"Randomized, controlled trial of an intervention for toddlers with autism: The Early Start Denver Model","volume":"125","author":"Dawson","year":"2010","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.pharmthera.2018.05.007_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044084","article-title":"Auditory processing in high-functioning adolescents with autism spectrum disorder","volume":"7","author":"DePape","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/DBP.0b013e3181d5aa6d","article-title":"Screening for autism spectrum disorders in children with down syndrome","volume":"31","author":"DiGuiseppi","year":"2010","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037961","article-title":"Do musicians with perfect pitch have more autism traits than musicians without perfect pitch? An empirical study","volume":"7","author":"Dohn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biopsych.2013.02.007","article-title":"Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder","volume":"74","author":"Domes","year":"2013","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.05.007_bb0220","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/aje\/kwn250","article-title":"Advanced parental age and the risk of autism spectrum disorder","volume":"168","author":"Durkin","year":"2008","journal-title":"American Journal of Epidemiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0225","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10803-005-0019-4","article-title":"Gastrointestinal factors in autistic disorder: A critical review","volume":"35","author":"Erickson","year":"2005","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"6301","key":"10.1016\/j.pharmthera.2018.05.007_bb0230","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1126\/science.aag3194","article-title":"Maternal immune activation: Implications for neuropsychiatric disorders","volume":"353","author":"Estes","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/08830738030180020501","article-title":"Application of a ketogenic diet in children with autistic behavior: Pilot study","volume":"18","author":"Evangeliou","year":"2003","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0240","first-page":"77","article-title":"A double-blind placebo-controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1992","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1023\/A:1021943802493","article-title":"The screening and diagnosis of autistic spectrum disorders","volume":"29","author":"Filipek","year":"1999","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.05.007_bb0250","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamapsychiatry.2014.83","article-title":"Atypical cross talk between mentalizing and mirror neuron networks in autism spectrum disorder","volume":"71","author":"Fishman","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/bjp.bp.108.051672","article-title":"Prenatal risk factors for autism: Comprehensive meta-analysis","volume":"195","author":"Gardener","year":"2009","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0260","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/cap.2008.0137","article-title":"Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit\/hyperactivity disorder symptoms in preschoolers with developmental disorders","volume":"19","author":"Ghuman","year":"2009","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2018.05.007_bb0265","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1007\/s10803-014-2128-4","article-title":"In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder","volume":"44","author":"Gidaya","year":"2014","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1362361301005001006","article-title":"The Asperger Syndrome (and high-functioning autism) Diagnostic Interview (ASDI): A preliminary study of a new structured clinical interview","volume":"5","author":"Gillberg","year":"2001","journal-title":"Autism"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.sxmr.2015.10.003","article-title":"Gender dysphoria and autism spectrum disorder: A systematic review of the literature","volume":"4","author":"Glidden","year":"2016","journal-title":"Sexual Medicine Reviews"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0280","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1588\/medver.2004.01.00029","article-title":"Digestion-gut-autism connection: The specific carbohydrate diet","volume":"1","author":"Gottschall","year":"2004","journal-title":"Medical Veritas"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0285","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0006-3223(01)01139-8","article-title":"Oxytocin and autistic disorder: Alterations in peptide forms","volume":"50","author":"Green","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0290","first-page":"87","article-title":"Developmental patterns and outcomes in infants and children with disorders in relating and communicating: A chart review of 200 cases of children with autistic spectrum diagnoses","volume":"1","author":"Greenspan","year":"1997","journal-title":"Journal of Developmental and Learning Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0295","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders","volume":"67","author":"Guastella","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0300","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/jcpp.12305","article-title":"The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: A randomized controlled trial","volume":"56","author":"Guastella","year":"2015","journal-title":"Journal of Child Psychology and Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.05.007_bb0305","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamapediatrics.2013.2188","article-title":"What DSM-5 could mean to children with autism and their families","volume":"167","author":"Halfon","year":"2013","journal-title":"JAMA Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0310","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1352\/0895-8017(2008)113[44:CSAABI]2.0.CO;2","article-title":"Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome","volume":"113","author":"Hall","year":"2008","journal-title":"American Journal of Mental Retardation"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.05.007_bb0315","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archgenpsychiatry.2011.76","article-title":"Genetic heritability and shared environmental factors among twin pairs with autism","volume":"68","author":"Hallmayer","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0320","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fpsyg.2011.00156","article-title":"Effects of practice and experience on the arcuate fasciculus: Comparing singers, instrumentalists, and non-musicians","volume":"2","author":"Halwani","year":"2011","journal-title":"Frontiers in Psychology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0325","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.05.007_bb0330","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/DBP.0b013e3181739b9d","article-title":"Guanfacine in children with autism and\/or intellectual disabilities","volume":"29","author":"Handen","year":"2008","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.05.007_bb0335","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10803-006-0192-0","article-title":"Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder","volume":"37","author":"Hanson","year":"2007","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0340","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","article-title":"Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders","volume":"35","author":"Hardan","year":"2005","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1522","key":"10.1016\/j.pharmthera.2018.05.007_bb0345","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1098\/rstb.2008.0327","article-title":"Assessing musical skills in autistic children who are not savants","volume":"364","author":"Heaton","year":"2009","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0350","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/1362361313493681","article-title":"Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders: A preliminary randomized controlled trial","volume":"18","author":"Hesselmark","year":"2014","journal-title":"Autism"},{"issue":"1430","key":"10.1016\/j.pharmthera.2018.05.007_bb0355","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1098\/rstb.2002.1197","article-title":"A retrospective analysis of the clinical case records of 'autistic psychopaths' diagnosed by Hans Asperger and his team at the University Children's Hospital, Vienna","volume":"358","author":"Hippler","year":"2003","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0360","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rasd.2017.10.003","article-title":"Cognitive-behavioral approaches for children with autism spectrum disorder: A trend analysis","volume":"45","author":"Ho","year":"2018","journal-title":"Research in Autism Spectrum Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0365","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biopsych.2006.05.030","article-title":"Oxytocin increases retention of social cognition in autism","volume":"61","author":"Hollander","year":"2007","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0370","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0375","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0380","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3945\/jn.116.242354","article-title":"\u03c9-3 fatty acid supplementation does not affect autism spectrum disorder in children: A systematic review and meta-analysis","volume":"147","author":"Horvath","year":"2017","journal-title":"The Journal of Nutrition"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0385","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1176\/appi.ajp.2012.12020276","article-title":"Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders","volume":"169","author":"Huerta","year":"2012","journal-title":"The American Journal of Psychiatry"},{"issue":"25","key":"10.1016\/j.pharmthera.2018.05.007_bb0390","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1301449","article-title":"Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism","volume":"369","author":"Hviid","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0395","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10803-006-0089-y","article-title":"Teaching reciprocal imitation skills to young children with autism using a naturalistic behavioral approach: Effects on language, pretend play, and joint attention","volume":"36","author":"Ingersoll","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0400","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0405","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.psychres.2013.01.005","article-title":"Parental psychiatric disorders and autism spectrum disorders","volume":"207","author":"Jokiranta","year":"2013","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0410","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4088\/JCP.12m07392","article-title":"Examining the comorbidity of bipolar disorder and autism spectrum disorders: A large controlled analysis of phenotypic and familial correlates in a referred population of youth with bipolar I disorder with and without autism spectrum disorders","volume":"74","author":"Joshi","year":"2013","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0415","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1176\/ajp.112.8.599","article-title":"Genetic aspects of preadolescent schizophrenia","volume":"112","author":"Kallman","year":"1956","journal-title":"The American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0420","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/17470910802198510","article-title":"Atypical frontal-posterior synchronization of theory of mind regions in autism during mental state attribution","volume":"4","author":"Kana","year":"2009","journal-title":"Social Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0425","first-page":"217","article-title":"Autistic disturbances of affective contact","volume":"2","author":"Kanner","year":"1943","journal-title":"The Nervous Child"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0430","first-page":"1","article-title":"How nutritional status, diet and dietary supplements can affect autism. A review","volume":"64","author":"Kawicka","year":"2013","journal-title":"Roczniki Pa\u0144stwowego Zak\u0142adu Higieny"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0435","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cbpra.2016.06.002","article-title":"Adapting cognitive behavioral techniques to address anxiety and depression in cognitively able emerging adults on the autism spectrum","volume":"23","author":"Kerns","year":"2016","journal-title":"Cognitive and Behavioral Practice"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0440","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0445","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10803-006-0229-4","article-title":"Social and communication abilities and disabilities in higher functioning individuals with autism spectrum disorders: The Vineland and the ADOS","volume":"37","author":"Klin","year":"2007","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0450","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s10803-013-1956-y","article-title":"Using self-management to improve the reciprocal social conversation of children with autism spectrum disorder","volume":"44","author":"Koegel","year":"2014","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0455","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1749-6632.2009.04592.x","article-title":"A neuroscientific perspective on music therapy","volume":"1169","author":"Koelsch","year":"2009","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0460","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1192\/bjp.118.545.381","article-title":"Studies in the childhood psychosis. I. Diagnostic criteria and classification","volume":"118","author":"Kolvin","year":"1971","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0465","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13034-015-0054-7","article-title":"The effectiveness of psychosocial interventions for anxiety in children and adolescents with autism spectrum disorder: A systematic review and meta-analysis","volume":"9","author":"Kreslins","year":"2015","journal-title":"Child and Adolescent Psychiatry and Mental Health"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0470","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1007\/s10803-014-2065-2","article-title":"How will DSM-5 affect autism diagnosis? A systematic literature review and meta-analysis","volume":"44","author":"Kulage","year":"2014","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0475","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1021\/acs.jmedchem.7b00965","article-title":"Targets for drug therapy for autism spectrum disorder: Challenges and future directions","volume":"60","author":"Lacivita","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0480","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(13)61539-1","article-title":"Autism","volume":"383","author":"Lai","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0485","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yfrne.2004.05.001","article-title":"Vasopressin and oxytocin release within the brain: A dynamic concept of multiple and variable modes of neuropeptide communication","volume":"25","author":"Landgraf","year":"2004","journal-title":"Frontiers in Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0490","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MOP.0b013e328336eb9a","article-title":"What causes autism? Exploring the environmental contribution","volume":"22","author":"Landrigan","year":"2010","journal-title":"Current Opinion in Pediatrics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0495","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/104454602762599853","article-title":"Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina","volume":"12","author":"Langworthy-Lam","year":"2002","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0500","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fnhum.2014.00268","article-title":"The co-occurrence of autism and attention deficit hyperactivity disorder in children - What do we know?","volume":"8","author":"Leitner","year":"2014","journal-title":"Frontiers in Human Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0505","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: Myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.05.007_bb0510","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10803-006-0123-0","article-title":"Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders","volume":"36","author":"Leyfer","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"36 Suppl","key":"10.1016\/j.pharmthera.2018.05.007_bb0515","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/13682820109177917","article-title":"Implementing the picture exchange communication system (PECS)","author":"Liddle","year":"2001","journal-title":"International Journal of Language & Communication Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0520","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/mp.2014.77","article-title":"The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: A meta-analysis","volume":"20","author":"LoParo","year":"2015","journal-title":"Molecular Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0525","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0530","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0535","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.ridd.2011.03.025","article-title":"Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome","volume":"32","author":"Lugnegard","year":"2011","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0540","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11920-012-0327-2","article-title":"What the DSM-5 portends for research, diagnosis, and treatment of autism spectrum disorders","volume":"14","author":"Mahjouri","year":"2012","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0545","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00004703-200504000-00002","article-title":"Relationship-focused early intervention with children with pervasive developmental disorders and other disabilities: A comparative study","volume":"26","author":"Mahoney","year":"2005","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0550","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1362361311402857","article-title":"Evaluation of the criterion and convergent validity of the diagnostic interview for social and communication disorders in young and low-functioning children","volume":"16","author":"Maljaars","year":"2012","journal-title":"Autism"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0555","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","article-title":"Olanzapine versus haloperidol in children with autistic disorder: An open pilot study","volume":"40","author":"Malone","year":"2001","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.05.007_bb0560","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0565","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022234605695","article-title":"Lowdose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study","volume":"33","author":"Martin","year":"2003","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0570","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/cap.1999.9.99","article-title":"Open-label quetiapine in the treatment of children and adolescents with autistic disorder","volume":"9","author":"Martin","year":"1999","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0575","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ridd.2007.09.006","article-title":"The validity of the autism spectrum disorders-diagnosis for intellectually disabled adults (ASD-DA)","volume":"29","author":"Matson","year":"2008","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0580","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.rasd.2010.06.012","article-title":"Anxiety, depression, and irritability in children with autism relative to other neuropsychiatry disorders and typical development","volume":"5","author":"Mayes","year":"2011","journal-title":"Research in Autism Spectrum Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0585","article-title":"Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: Systematic review and meta-analysis of case-control and randomised controlled trials","author":"Mazahery","year":"2018","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0590","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0595","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00004714-199802000-00010","article-title":"Sertraline in adults with pervasive developmental disorders: A prospective, open-label investigation","volume":"18","author":"McDougle","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.05.007_bb0600","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders","volume":"55","author":"McDougle","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0605","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","article-title":"Case series: Use of ziprasidone for maladaptive symptoms in youths with autism","volume":"41","author":"McDougle","year":"2002","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0610","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","article-title":"A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder","volume":"53","author":"McDougle","year":"1996","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0615","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/cap.2008.0123","article-title":"Omega 3 fatty acid treatment in autism","volume":"19","author":"Meiri","year":"2009","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.05.007_bb0620","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00004583-198907000-00012","article-title":"Use of the childhood autism rating scale with autistic adolescents and adults","volume":"28","author":"Mesibov","year":"1989","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0625","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.braindev.2007.12.007","article-title":"Use of clonidine in children with autism spectrum disorders","volume":"30","author":"Ming","year":"2008","journal-title":"Brain and Development"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0630","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0006-3223(97)00439-3","article-title":"Plasma oxytocin levels in autistic children","volume":"43","author":"Modahl","year":"1998","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0635","first-page":"375","article-title":"Characteristics of school-age children with autism","volume":"26","author":"Montes","year":"2006","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2018.05.007_bb0640","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jad.2008.02.015","article-title":"High prevalence of bipolar disorder comorbidity in adolescents and young adults with high-functioning autism spectrum disorder: A preliminary study of 44 outpatients","volume":"111","author":"Munesue","year":"2008","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0645","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0887-6185(98)00022-X","article-title":"Comorbid anxiety symptoms in children with pervasive developmental disorders","volume":"12","author":"Muris","year":"1998","journal-title":"Journal of Anxiety Disorders"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0650","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/npy.11.62","article-title":"Treatment of comorbid anxiety and autism spectrum disorders","volume":"1","author":"Nadeau","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0655","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00004703-200304000-00005","article-title":"Use of citalopram in pervasive developmental disorders","volume":"24","author":"Namerow","year":"2003","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0660","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/17518423.2012.697492","article-title":"A comparison of diagnostic criteria on the Autism Spectrum Disorder Observation for Children (ASD-OC)","volume":"15","author":"Neal","year":"2012","journal-title":"Developmental Neurorehabilitation"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0665","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/19315864.2012.704490","article-title":"Validity of the Autism Spectrum Disorder Observation for Children (ASD-OC)","volume":"7","author":"Neal","year":"2014","journal-title":"Journal of Mental Health Research in Intellectual Disabilities"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0670","article-title":"Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children","volume":"45","author":"Newcorn","year":"1998","journal-title":"Pediatric Clinics of North America"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0675","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/ejcn.2015.28","article-title":"Omega-3 fatty acids in the management of autism spectrum disorders: Findings from an open-label pilot study in Singapore","volume":"69","author":"Ooi","year":"2015","journal-title":"European Journal of Clinical Nutrition"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0680","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0685","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.chi.0000153229.80215.a0","article-title":"An open-label trial of escitalopram in pervasive developmental disorders","volume":"44","author":"Owley","year":"2005","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0690","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/02646830500381930","article-title":"Immunity, neuroglia and neuroinflammation in autism","volume":"17","author":"Pardo","year":"2005","journal-title":"International Review of Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0695","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbr.2008.12.016","article-title":"Immune involvement in schizophrenia and autism: Etiology, pathology and animal models","volume":"204","author":"Patterson","year":"2009","journal-title":"Behavioural Brain Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.05.007_bb0700","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/npp.2017.7","article-title":"Materanl immune activation causes behavioral impairments and altered cerebellar cytokine and synaptic protein expression","volume":"42","author":"Pendyala","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0705","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/JCI32483","article-title":"Antipsycohtics in the treatment of autism","volume":"118","author":"Posey","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0710","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/cap.1999.9.273","article-title":"Risperidone in the treatment of two very young children with autism","volume":"9","author":"Posey","year":"1999","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0715","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004714-199902000-00008","article-title":"Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study","volume":"19","author":"Potenza","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0720","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder","volume":"25","author":"Quintana","year":"1995","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0725","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1362361312470494","article-title":"Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders","volume":"18","author":"Rao","year":"2014","journal-title":"Autism"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0730","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/CHI.0b013e31818b1c63","article-title":"Autism spectrum disorders and childhood-onset schizophrenia: Clinical and biological contributions to a relation revisited","volume":"48","author":"Rapoport","year":"2009","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0740","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1021\/jm501745f","article-title":"Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach","volume":"58","author":"Ratni","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0745","doi-asserted-by":"crossref","first-page":"e1845","DOI":"10.1542\/peds.2006-0338","article-title":"Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3\u202fyears of life among inner-city children","volume":"118","author":"Rauh","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0750","article-title":"Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD)","volume":"10","author":"Reichow","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0755","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","author":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0760","author":"Roche Press Release"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0765","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1155\/2011\/405849","article-title":"Parent report of community psychiatric comorbid diagnoses in autism spectrum disorders","volume":"2011","author":"Rosenberg","year":"2011","journal-title":"Autism Research and Treatment"},{"issue":"10","key":"10.1016\/j.pharmthera.2018.05.007_bb0770","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpediatrics.2009.98","article-title":"Characteristics and concordance of autism spectrum disorders among 277 twin pairs","volume":"163","author":"Rosenberg","year":"2009","journal-title":"Archives of Pediatrics & Adolescent Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0775","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1192\/bjp.186.6.525","article-title":"Obsessions and compulsions in Asperger syndrome and high-functioning autism","volume":"186","author":"Russell","year":"2005","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0780","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00004583-198905000-00017","article-title":"The phenomenology of schizophrenia occurring in childhood","volume":"28","author":"Russell","year":"1989","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0785","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1352\/0895-8017(2005)110[417:IBTFCW]2.0.CO;2","article-title":"Intensive behavioral treatment for children with autism: Four-year outcome and predictors","volume":"110","author":"Sallows","year":"2005","journal-title":"American Journal of Mental Retardation"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0790","article-title":"Nutritional and dietary interventions for autism spectrum disorder: A systematic review","author":"Sathe","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0795","series-title":"Evidence-based practices and treatments for children with autism","first-page":"231","article-title":"Psychopharmacology in children with PDD: Review of current evidence","author":"Scahill","year":"2011"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.05.007_bb0800","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-eelease guanfacine for hyperactivity in children with autism spectrum disorder","volume":"172","author":"Scahill","year":"2015","journal-title":"The American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0805","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1542\/peds.2007-1049","article-title":"Birth weight and gestational age characteristics of children with autism, including a comparison with other developmental disabilities","volume":"121","author":"Schendel","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0810","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1749-6632.2009.04587.x","article-title":"Evidence for plasticity in white matter tracts of chronic aphasic patients undergoing intense intonation-based speech therapy","volume":"1169","author":"Schlaug","year":"2009","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.05.007_bb0815","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF02408436","article-title":"Toward objective classification of childhood autism: Childhood autism rating scale (CARS)","volume":"10","author":"Schopler","year":"1980","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0825","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/aur.1437","article-title":"Fronto-temporal connectivity is preserved during sung but not spoken word listening, across the autism spectrum","volume":"8","author":"Sharda","year":"2015","journal-title":"Autism Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0830","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2018.05.007_bb0835","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1542\/peds.2012-0900G","article-title":"Attention-deficit\/hyperactivity disorder symptoms, adaptive functioning, and quality of life in children with autism spectrum disorder","volume":"130","author":"Sikora","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0840","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","article-title":"Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample","volume":"47","author":"Simonoff","year":"2008","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0845","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000435787","article-title":"Overlap between autism spectrum disorder and bipolar affective disorder","volume":"48","author":"Skokauskas","year":"2015","journal-title":"Psychopathology"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0850","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00004583-200405000-00008","article-title":"The developmental, dimensional and diagnostic interview (3di): A novel computerized assessment for autism spectrum disorders","volume":"43","author":"Skuse","year":"2004","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0855","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1023\/A:1026052421693","article-title":"Autism and tuberous sclerosis","volume":"28","author":"Smalley","year":"1998","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0860","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S53009","article-title":"Antidepressant exposure in pregnancy and risk of autism spectrum disorders","volume":"5","author":"S\u00f8rensen","year":"2013","journal-title":"Clinical Epidemiology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0865","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/1362361315587659","article-title":"Group social skills interventions for adults with high-functioning autism spectrum disorders: A systematic review","volume":"19","author":"Spain","year":"2015","journal-title":"Autism"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.05.007_bb0870","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10567-011-0097-0","article-title":"Anxiety disorders in children and adolescents with autistic spectrum disorders: A meta-analysis","volume":"14","author":"van Steensel","year":"2011","journal-title":"Clinical Child and Family Psychology Review"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0875","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/cap.1997.7.9","article-title":"Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder","volume":"7","author":"Steingard","year":"1997","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0880","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1542\/peds.2013-1193","article-title":"Cognitive-behavioral therapy for anxiety in children with high-functioning autism: A meta-analysis","volume":"132","author":"Sukhodolsky","year":"2013","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.pharmthera.2018.05.007_bb0885","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1176\/appi.ajp.2012.12070922","article-title":"Sensitivity and specificity: DSM-IV versus DSM-5 criteria for autism spectrum disorder","volume":"169","author":"Tsai","year":"2012","journal-title":"The American Journal of Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.05.007_bb0890","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"Tschoner","year":"2007","journal-title":"International Journal of Clinical Practice"},{"issue":"9","key":"10.1016\/j.pharmthera.2018.05.007_bb0895","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/npp.2016.232","article-title":"A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder","volume":"42","author":"Umbricht","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0900","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10578-014-0494-y","article-title":"A systematic review and meta-analysis of cognitive-behavioral therapy for anxiety in youth with high-functioning autism spectrum disorders","volume":"46","author":"Ung","year":"2015","journal-title":"Child Psychiatry and Human Development"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0905","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jad.2014.06.042","article-title":"Bipolar disorder in adults with Asperger's syndrome: A systematic review","volume":"168","author":"Vannucchi","year":"2014","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0910","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev.clinpsy.121208.131151","article-title":"Behavioral treatments in autism spectrum disorder: What do we know?","volume":"6","author":"Vismara","year":"2010","journal-title":"Annual Review of Clinical Psychology"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0915","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012036","article-title":"Diagnostic instruments for autism spectrum disorder (ASD)","author":"Vllasaliu","year":"2016","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0920","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1093\/brain\/awv249","article-title":"Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism","volume":"138","author":"Watanabe","year":"2015","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.05.007_bb0925","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1469-7610.1988.tb00759.x","article-title":"Symptom development in childhood onset schizophrenia","volume":"29","author":"Watkins","year":"1988","journal-title":"Journal of Child Psychology and Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0930","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cpr.2016.08.001","article-title":"Effectiveness of cognitive behavioural therapy with people who have autistic spectrum disorders: A systematic review and meta-analysis","volume":"49","author":"Weston","year":"2016","journal-title":"Clinical Psychology Review"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0935","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s10803-009-0801-9","article-title":"Preliminary efficacy of a cognitive-behavioral treatment program for anxious youth with autism spectrum disorders","volume":"39","author":"White","year":"2009","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0940","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cpr.2009.01.003","article-title":"Anxiety in children and adolescents with autism spectrum disorders","volume":"29","author":"White","year":"2009","journal-title":"Clinical Psychology Review"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0945","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1179\/147683010X12611460763922","article-title":"The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders","volume":"13","author":"Whiteley","year":"2010","journal-title":"Nutritional Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.05.007_bb0950","first-page":"50","article-title":"Development and classification of an operational definition of complementary and alternative medicine for the Cochrane Collaboration","volume":"17","author":"Wieland","year":"2011","journal-title":"Alternative Therapies in Health and Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0955","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004677.pub2","article-title":"Selective serotonin reuptake inhibitors for autism spectrum disorders","volume":"8","author":"Williams","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0960","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/1469-7610.00023","article-title":"The diagnostic interview for social and communication disorders: Background, inter-rater reliability and clinical use","volume":"43","author":"Wing","year":"2002","journal-title":"Journal of Child Psychology and Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0965","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2015.162","article-title":"The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial","volume":"21","author":"Yatawara","year":"2016","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.007_bb0970","series-title":"Estimated prevalence of children with diagnosed developmental disabilities in the United States, 2014\u20132016. NCHS Data Brief, no 291","author":"Zablotsky","year":"2017"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.05.007_bb0975","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.braindev.2006.09.003","article-title":"Childhood autism and associated comorbidities","volume":"29","author":"Zafeiriou","year":"2007","journal-title":"Brain & Development"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818300871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818300871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T17:31:45Z","timestamp":1604251905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818300871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":193,"alternative-id":["S0163725818300871"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.007","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autism Spectrum Disorder: Classification, diagnosis and therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}